List of Excipients in Branded Drug LINCOCIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	LINCOCIN	lincomycin hydrochloride	0009-0555	BENZYL ALCOHOL

Lincomycin Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Lincomycin, marketed historically as Lincocin, is an old lincosamide antibiotic with no meaningful remaining originator exclusivity. The commercial opportunity is therefore formulation-led rather than patent-led. The strongest opportunities are preservative-free injectable products, ready-to-use presentations, improved oral liquids, and differentiated veterinary formulations. The principal technical constraints are injection-site tolerability, preservative exposure, aqueous stability, taste, container compatibility, and regulatory acceptance of excipient changes.

What is the FDA and commercial status of Lincocin?

Lincocin is the brand name historically associated with lincomycin hydrochloride, the hydrochloride salt of lincomycin. The drug has been used for susceptible serious bacterial infections, although clindamycin has displaced lincomycin in many human indications because of broader clinical use and more convenient dosing.

Item	Assessment
Active ingredient	Lincomycin hydrochloride
Drug class	Lincosamide antibacterial
Historical brand	Lincocin
Originator	The Upjohn Company, later associated with Pfizer
Main dosage forms	Injectable solution, capsules; historical oral liquid presentations
U.S. regulatory pathway	Legacy NDA and subsequent generic opportunities
Current exclusivity	No material FDA marketing exclusivity remaining
Patent position	Core composition and use patents are expired
Biosimilar exposure	None; lincomycin is a small-molecule drug
Main commercial barrier	Market size, clinical substitution by clindamycin, manufacturing economics
Main formulation opportunity	Differentiated injectable and liquid products

FDA records should be checked by product, strength, dosage form, and NDC because historical Lincocin listings and current generic availability may differ. A product listed as discontinued in FDA databases is not necessarily withdrawn for safety reasons. It may reflect commercial discontinuation or the absence of an active marketed NDC. [1,2]

What formulations are protected by Lincocin patents?

No active U.S. exclusivity is expected to protect the historical Lincocin formulation. Lincomycin was introduced in the 1960s, and the basic active ingredient, salt, conventional dosage forms, and early therapeutic uses are well beyond ordinary patent terms.

The relevant intellectual-property position is therefore divided into two categories:

IP category	Current relevance
Lincomycin molecule	Expired
Lincomycin hydrochloride salt	Expired or commercially nonexclusive
Conventional capsules	No meaningful exclusivity
Conventional aqueous injection	No meaningful exclusivity
Historical method-of-use claims	Expired or commercially weak
New delivery system	Potentially patentable if technically distinctive
New excipient combination	Potentially patentable only if nonobvious and supported by data
Manufacturing process	Potentially protectable, but usually difficult to enforce against generic manufacturers
Packaging and device configuration	Potentially protectable if the presentation is distinctive

A new patent would need to claim more than the use of a known excipient in a known lincomycin dosage form. A viable formulation patent would normally require a defined composition, a measurable stability or tolerability advantage, and comparative data against conventional lincomycin products.

Can excipients create new lincomycin patent protection?

Potentially, but the threshold is high. Broad claims covering lincomycin plus common excipients such as water, sodium hydroxide, lactose, starch, or magnesium stearate would face substantial novelty and obviousness challenges.

More defensible claim areas include:

• A preservative-free injectable composition with a defined pH and impurity profile.
• A ready-to-use container system that maintains potency without reconstitution.
• A taste-masked oral liquid with a specified dissolution and palatability profile.
• A low-volume injectable formulation with reduced injection-site pain.
• A stable formulation using a nontraditional buffering or chelating system.
• A lyophilized product with defined reconstitution time and stability.
• A dual-compartment presentation that separates incompatible components until administration.

Patent value would depend on whether the formulation solves a documented clinical or manufacturing problem. A patent on a minor excipient substitution without a demonstrated technical effect would have limited blocking power.

What excipients are used in Lincocin products?

Historical lincomycin products have used different excipient systems depending on dosage form and manufacturer. The exact composition must be confirmed against the applicable package insert or current DailyMed entry.

Injectable lincomycin

Historical Lincocin injection labeling identifies lincomycin hydrochloride in an aqueous sterile solution. Benzyl alcohol has been used as a preservative in some injectable presentations, and pH adjustment may involve sodium hydroxide or hydrochloric acid. The exact excipient list varies by strength, container, and manufacturer. [3]

The commercial excipient issues are:

1. Benzyl alcohol exposure, particularly in neonates and small infants.
2. Injection-site pain and local tolerability.
3. Stability during storage and after opening.
4. Compatibility with polypropylene syringes, glass vials, infusion bags, and elastomeric closures.
5. Particulate control and extractables from the container system.
6. Need for low-volume dosing in hospital settings.

A preservative-free version could have a clearer value proposition in neonatal, pediatric, oncology, and hospital procurement channels, subject to the approved indication and appropriate clinical positioning.

Oral capsules

Historical lincomycin capsules generally use conventional solid-dose excipients such as lactose or another diluent, starch or a disintegrant, magnesium stearate, gelatin, titanium dioxide, and permitted colorants. The actual formula depends on the manufacturer and capsule strength. [4]

The capsule presents limited formulation differentiation. Generic manufacturers can usually reproduce the dosage form at low cost. Opportunities are more likely to come from:

• Improved moisture protection.
• Lower lactose or lactose-free formulations.
• Smaller capsule size.
• Modified-release delivery.
• Unit-dose packaging.
• Hospital and institutional packaging.
• Supply reliability rather than pharmaceutical novelty.

Oral liquid

An oral liquid has greater excipient complexity because lincomycin is intensely bitter. A commercially useful liquid would need a robust taste-masking system, adequate preservative protection, acceptable viscosity, and sufficient chemical and microbiological stability.

Potential excipient categories include:

Function	Candidate strategy
Taste masking	Ion-exchange resin, polymeric complexation, sweetener and flavor system
Suspending	Cellulose derivatives, xanthan gum, or other pharmaceutically accepted suspending agents
Preservation	Preservative system selected through antimicrobial effectiveness testing
Buffering	Controlled pH system that limits degradation and maintains palatability
Mouthfeel	Polyols or viscosity modifiers
Packaging	Amber bottle, child-resistant closure, oral syringe
Stability	Unit-dose or powder-for-reconstitution presentation

A powder-for-reconstitution product may offer better shelf life than a ready-to-use liquid. Its commercial value would depend on whether the reconstituted product remains stable for a useful in-use period and whether the taste profile is materially better than existing alternatives.

What is the strongest excipient strategy for lincomycin injection?

The strongest near-term strategy is a preservative-free, ready-to-use injectable product in a modern container system.

Preservative-free single-dose injection

A single-dose vial or prefilled syringe could remove benzyl alcohol exposure and simplify hospital administration. The formulation would need to demonstrate:

• Chemical stability through the proposed shelf life.
• Sterility assurance.
• Particulate compliance.
• Container-closure integrity.
• Compatibility with the delivery device.
• Acceptable osmolality and pH.
• Acceptable local tolerability.
• Stability after dilution into commonly used infusion solutions, if dilution is part of the proposed labeling.

The product would compete on safety profile, workflow, and supply reliability rather than on molecular differentiation.

Ready-to-use presentation

A ready-to-use syringe or small-volume vial could reduce pharmacy compounding and preparation time. The key commercial questions are whether hospitals currently reconstitute or dilute the product, whether the dose is predictable enough for prefilled delivery, and whether the packaging cost can be supported by institutional pricing.

Low-volume concentrated formulation

A higher-concentration formulation could reduce injection volume, but concentration increases the risk of precipitation, local irritation, osmolality problems, and stability failures. This strategy is technically attractive but requires strong comparative data.

Infusion-compatible formulation

A product packaged for direct dilution into common infusion fluids could target hospital workflow. The formulation must be assessed for precipitation, adsorption, color change, pH drift, and potency loss. These data could support labeling differentiation even if they do not create durable patent protection.

What commercial opportunities exist for lincomycin oral products?

The oral market is more constrained than the injectable market. Clindamycin has a stronger position in many human treatment settings, and generic lincomycin capsules are relatively easy to manufacture.

The most viable oral opportunities are:

1. A palatable pediatric oral liquid or powder for reconstitution.
2. A lactose-free capsule for institutions and patients with excipient sensitivities.
3. A moisture-protected capsule with extended shelf life.
4. An institutional unit-dose package.
5. A veterinary oral formulation with improved administration characteristics.
6. A modified-release formulation, if clinical dosing and pharmacokinetics support the investment.

A modified-release product would require more than an excipient change. It would need pharmacokinetic and clinical justification, with a regulatory pathway likely more complex than a conventional ANDA.

How does lincomycin compare with clindamycin commercially?

Clindamycin is the principal commercial comparator because it is also a lincosamide and has broader contemporary clinical recognition.

Factor	Lincomycin	Clindamycin
Market maturity	Legacy product	Established generic product
Human clinical use	Narrower and declining in many settings	Broader
Formulation opportunity	Injectable and oral-liquid niches	Larger but more competitive
Taste challenge	Significant	Significant
Patent leverage	Minimal	Mostly expired for conventional products
Hospital differentiation	Preservative-free and workflow improvements	Stronger existing generic competition
Veterinary opportunity	Relevant	Also competitive
Commercial ceiling	Limited in human medicine	Higher

Lincomycin may still have value where susceptibility, formulary policy, supply constraints, or veterinary demand support its use. The product should not be positioned as a broad replacement for clindamycin without clinical and regulatory support.

When does Lincocin lose exclusivity?

Lincocin has already lost its core exclusivity. The original active ingredient, conventional salt, capsule, and injectable presentations are outside the normal U.S. patent term.

Exclusivity type	Status
New chemical entity exclusivity	Expired
Orphan exclusivity	Not established for the core product
Pediatric exclusivity	No current commercial relevance
Core composition patent	Expired
Conventional formulation patents	Expired or commercially immaterial
Method-of-use patents	Historical claims are not expected to block current entry
Data exclusivity	No current barrier for a conventional generic

Patent expiry does not guarantee commercial availability. A manufacturer still must satisfy FDA quality, manufacturing, bioequivalence, labeling, and supply requirements.

What is the Orange Book status of Lincocin?

The Orange Book should be reviewed at the individual product level because historical brand products, discontinued products, and generic products can appear differently across FDA databases. The principal regulatory points are:

• Lincocin is not expected to have a live Orange Book patent barrier protecting its basic composition.
• Any current ANDA applicant would need to evaluate listed patents associated with the specific reference product.
• A discontinued brand listing does not automatically establish a safety withdrawal.
• Product-specific status, strength, dosage form, and marketing status must be confirmed in the current FDA database. [1]

For a conventional lincomycin capsule or injection, the regulatory path is generally more likely to be an ANDA if an appropriate reference product is available. A materially new formulation, delivery system, or clinical use could require a 505(b)(2) application.

Are there Paragraph IV challenges or lincomycin patent lawsuits?

No material current Paragraph IV campaign, settlement agreement, or active U.S. patent litigation is associated with the historical Lincocin formulation in the principal FDA and public patent litigation sources reviewed for this analysis.

The absence of litigation is consistent with the commercial profile:

• The core patents are old.
• The product market is limited.
• Conventional formulations are readily substitutable.
• The value of a new entrant depends more on manufacturing and distribution than on blocking patents.

A new formulation could create litigation risk if it receives Orange Book-listed patents and captures a meaningful hospital or specialty market. That risk would arise from the new formulation, not from the legacy Lincocin product.

What manufacturing and IP barriers affect lincomycin?

The active ingredient is not the primary barrier. The main barriers are operational.

Manufacturing barriers

• Consistent sterile manufacturing for injectable products.
• Control of impurities and degradation products.
• Reliable sourcing of lincomycin hydrochloride.
• Container-closure compatibility.
• Preservative-free sterility assurance.
• Low particulate levels.
• Batch-to-batch taste consistency for oral liquids.
• Microbiological control after reconstitution.
• Global variation in acceptable excipient limits.

IP barriers

A new entrant could protect:

• A device-enabled injectable presentation.
• A defined stability-enhancing excipient combination.
• A taste-masked liquid.
• A combination of concentration, pH, buffer, and container system.
• A manufacturing process that reduces a specified impurity.
• A veterinary dosage form with a distinct release profile.

Process patents are less effective when competitors can make the same product through an alternative process. Formulation patents have greater commercial value when the protected composition is difficult to design around and is tied to a meaningful regulatory or clinical advantage.

What geographic opportunities exist?

The best geographic opportunity may be outside the U.S., where lincomycin remains relevant in veterinary medicine and in selected human markets. The strategy differs by region.

Region	Opportunity
United States	Hospital injectable niche, preservative-free product, institutional supply
European Union	Veterinary and selected human generic opportunities, subject to national authorization
Latin America	Oral and injectable supply, local registration and price sensitivity
Asia-Pacific	Human and veterinary demand, local manufacturing competition
Emerging markets	Basic injectable and oral products, procurement-driven competition

International excipient acceptance must be reviewed separately. A formulation acceptable in the U.S. may require different preservative, colorant, flavor, or packaging justification elsewhere. Veterinary products may also follow separate national or regional pathways.

What is the revenue exposure and investment case?

Public company disclosures generally do not provide a separately reported revenue figure for Lincocin or generic lincomycin. The product should therefore be evaluated as a niche, low-exclusivity asset rather than as a large branded-drug opportunity.

Revenue upside is most credible in four channels:

1. Hospital injectable supply.
2. Veterinary products.
3. Pediatric or geriatric oral liquids.
4. Markets with recurring generic shortages or limited local competition.

A conventional capsule launch is unlikely to support a strong return unless the manufacturer has low-cost active-ingredient access, existing sterile capacity, or a distribution advantage. A differentiated injectable product could command better institutional pricing, but the development and quality-control costs are materially higher.

What is the generic launch risk for Lincocin?

Generic launch risk is high for conventional dosage forms because:

• Core patents are expired.
• Excipients are mostly conventional.
• The product is a small molecule.
• No biosimilar pathway is relevant.
• Design-around options are extensive.
• Manufacturing technology is established.

Risk is lower for a differentiated product if the applicant owns formulation or device patents, controls a difficult-to-source component, or has strong hospital contracts. Regulatory approval alone would not prevent competing generics unless the product earns enforceable patent protection or market exclusivity.

Key Takeaways

• Lincocin is a legacy lincomycin brand with no meaningful remaining core exclusivity.
• The commercial opportunity is formulation-led, not molecule-led.
• Preservative-free injectable lincomycin is the strongest human-health opportunity.
• Ready-to-use syringes, low-volume vials, and infusion-compatible presentations could improve hospital value.
• Oral liquids require credible taste masking, microbial preservation, and reconstitution stability.
• Conventional capsules have limited differentiation and high generic launch risk.
• No current biosimilar issue exists because lincomycin is a small molecule.
• No material current Paragraph IV campaign or settlement is associated with the legacy formulation in the principal public sources reviewed.
• Veterinary markets may offer greater commercial potential than the declining human branded market.
• A new patent would need to cover a technically meaningful formulation, delivery system, packaging configuration, or manufacturing improvement.

FAQs

Can benzyl alcohol be removed from Lincocin injection?

Yes, a preservative-free formulation is technically possible, but it requires a validated sterile single-dose presentation, container-closure data, stability studies, and appropriate regulatory support.

Is lincomycin oral liquid commercially attractive?

It can be attractive in pediatric, veterinary, and institutional settings if the product solves bitterness, dosing accuracy, and post-reconstitution stability problems.

Can a new excipient create a patent for lincomycin?

A new excipient alone is unlikely to support a strong patent. The formulation would need a defined composition and evidence of an unexpected stability, tolerability, delivery, or clinical benefit.

Does lincomycin have biosimilar competition?

No. Lincomycin is a small-molecule antibiotic and competes through generic-drug pathways rather than the biosimilar pathway.

Is Lincocin still a protected branded product?

No material core patent or regulatory exclusivity is expected to protect the historical Lincocin product. Current product status should be verified by specific FDA listing and NDC.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. DailyMed. (n.d.). Lincomycin hydrochloride injection prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

4. DailyMed. (n.d.). Lincomycin hydrochloride capsules prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/